Drug Profile
Research programme: glycan based therapeutics - CHO Pharma
Alternative Names: CHO S05; CHO V07; Dual-effect anti-flu drugsLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Academia Sinica
- Developer CHO Pharma
- Class Antivirals; Vaccines
- Mechanism of Action Cytokine inhibitors; Influenza A virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Influenza-virus-infections in Taiwan (PO)
- 20 Jul 2017 CHO Pharma has patent protection for glycan based vaccine and drugs in USA, Europe, South Korea, Japan, Canada, China and Australia (CHO Pharma website, July 2017)
- 20 Jul 2017 CHO Pharma has patents pending for glycan based vaccine and drugs in Taiwan (CHO Pharma website, July 2017)